Who are DEB-TACE plus Lenvatinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deb-tace-plus-lenvatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DEB-TACE plus Lenvatinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DEB-TACE plus Lenvatinib (DEB-TACE plus Lenvatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: locoregional chemotherapy + multi-kinase inhibitor. Area: Oncology.

phase 3 Combination therapy: locoregional chemotherapy + multi-kinase inhibitor DEB-TACE: topoisomerase II (doxorubicin); Lenvatinib: FGFR, VEGFR, RET, KIT, PDGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DEB-TACE plus Lenvatinib (DEB-TACE plus Lenvatinib) — Guangxi Medical University. DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DEB-TACE plus Lenvatinib TARGET	DEB-TACE plus Lenvatinib	Guangxi Medical University	phase 3	Combination therapy: locoregional chemotherapy + multi-kinase inhibitor	DEB-TACE: topoisomerase II (doxorubicin); Lenvatinib: FGFR, VEGFR, RET, KIT, PDGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: locoregional chemotherapy + multi-kinase inhibitor class)

Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DEB-TACE plus Lenvatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/deb-tace-plus-lenvatinib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing